Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...

Learn the vital steps to take when someone experiences a severe asthma attack, from recognizing danger signs to administering ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab) comes just four months after the TSLP inhibitor became the first biologic therapy for severe asthma to be ...

Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.